显著降低了前列腺癌的发病率,并在25年内改善了前列腺癌的存活率
Bernat Carles Serdà-Ferrer1, Arantza Sanvisens2, Rafael Fuentes-Raspall3
1Department of Nursing, Universitat de Girona, 17003, Girona, Spain. bernat.serda@udg.edu.
BMC public health
|December 22, 2023
概括
在西班牙吉罗纳,前列腺癌 (PCa) 发病率在2003年后下降,而生存率在25年内显著改善. 这些发现突显了管理男性这种常见癌症的进展.
科学领域:
- 在瘤学瘤学.
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 前列腺癌 (PCa) 是全球男性癌症死亡的主要原因.
- 分析PCa发病率,死亡率和生存率的长期趋势对于公共卫生规划至关重要.
- 这项研究侧重于西班牙吉罗纳的PCa趋势,长达25年.
研究的目的:
- 分析西班牙吉罗纳的前列腺癌发病率和死亡率的时间趋势.
- 为了评估前列腺癌存活率在25年的变化.
- 为癌症控制策略的有效性提供见解.
主要方法:
- 基于基隆癌症注册局 (1994-2018) 数据的基于人口的研究.
- 根据年龄调整的发病率和死亡率每10万男性/年计算.
- 结点回归模型用于趋势分析和Kaplan-Meier/Pohar-Perme对生存的估计.
主要成果:
- 共有9,846个PCa案件被注册.
- 发病率增加了6.2% (1994-2003) 然后下降了-2.7% (2003-2018).
- 死亡率呈现稳定的下降 (APC -2.6%),五年净生存率从72.9%提高到91.3%.
结论:
- 从2003年开始观察到前列腺癌发病率的显著降低.
- 在研究期间,前列腺癌总体存活率大幅增加.
- 这些趋势表明干预措施的积极影响和PCa管理的改善.
相关概念视频
Cancer Survival Analysis
355
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
355
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


